@article{70bd2587f86947b5956b35e778f95926,
title = "American Academy of Periodontology best evidence consensus statement on modifying periodontal phenotype in preparation for orthodontic and restorative treatment",
author = "Kao, \{Richard T.\} and Curtis, \{Donald A.\} and Kim, \{David M.\} and Lin, \{Guo Hao\} and Wang, \{Chin Wei\} and Cobb, \{Charles M.\} and Hsu, \{Yung Ting\} and Joseph Kan and Diego Velasquez and Gustavo Avila-Ortiz and Yu, \{Shan Huey\} and Mandelaris, \{George A.\} and Rosen, \{Paul S.\} and Marianna Evans and John Gunsolley and Katie Goss and Jeanne Ambruster and Wang, \{Hom Lay\}",
note = "Funding Information: The American Academy of Periodontology best evidence consensus meeting on periodontal phenotype was sponsored by Geistlich Pharma AG (Root, Switzerland). Participants filed detailed disclosure of potential conflicts of interest relevant to the meeting topic, and these are kept on file. The authors receive, or have received, advisor fees and/or lecture compensation from the following companies: BioHorizons (Birmingham, Alabama), Geistlich Pharma, and Neoss (Harrogate, North Yorkshire, United Kingdom). Katie Goss is the associate executive director of science and clinical affairs at the American Academy of Periodontology.",
year = "2020",
month = mar,
doi = "10.1002/JPER.19-0577",
language = "English",
volume = "91",
pages = "289--298",
journal = "Journal of Periodontology",
issn = "0022-3492",
number = "3",
}